Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Extension Study with Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients with IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

NCT03512314 is registered in ClinicalTrials.gov with AB2 Bio Ltd. as lead sponsor.

NCT NCT03512314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03512314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Extension Study with Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients with IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Lead sponsor
AB2 Bio Ltd.
Phase
Phase 3
Overall status
Completed
Start date
January 24, 2018
Completion date
May 8, 2024
Enrollment
11 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

nlrc4-mas, xiap deficiency